A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
Awakn Life Sciences has announced that it has signed a five-year lease to open Awakn Clinics Trondheim.
Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners in the field of psychedelic therapies.
Irwin Naturals is branching into the psychedelics space with the aim of establishing the world’s largest chain of psychedelic mental health clinics.
An increasing amount of research is investigating the efficacy of psychedelic mushrooms for the treatment of a number of health conditions, however, knowledge about how psychedelic...
KGK Science and Nova Mentis Life Science will carry out a Phase 2a clinical trial testing the efficacy of psilocybin microdosing on Fragile X Syndrome.
Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.
Clearmind Medicine will be embarking on a first-in-human clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Biopharmaceutical company, Silo Pharma, has announced plans to study its novel joint homing peptide in the treatment of rheumatoid arthritis.